Physician profile
Asma Anwar
NPI 1972773539
$584.60
in general payments reported to CMS, 2019-2025
15 companies · $85.79 in 2025
The $85.79 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $128 · 2021: $55.76 · 2022: $59.29 · 2023: $15.41 · 2024: $24.15 · 2025: $85.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $125.18 | 2019-2020 | |
| Glaxosmithkline, LLC. | $98.44 | 2022-2025 | Jemperli |
| Boston Scientific Corporation | $57.27 | 2020-2023 | Solyx Sis System |
| Janssen Biotech, INC. | $44.01 | 2019-2022 | |
| Abbvie INC. | $39.13 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $38.28 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $36.11 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.75 | 2022 | |
| Secura Bio, INC. | $19.53 | 2019 | |
| Puma Biotechnology, INC. | $19.25 | 2019 | |
| Welch Allyn | $16.78 | 2021 | |
| Pfizer INC. | $16.04 | 2020 | |
| Eisai INC. | $15.90 | 2020 | |
| Foundation Medicine, INC. | $14.01 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asma Anwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.